Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioSelect: Biomarker-Guided Antidepressant Selection for Treatment-Resistant Depression
NCT07680140Phase 4Recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Aug 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 4 trial of ketamine in treatment-resistant depression (TRD), sponsored by Weill Cornell Medicine. Started Aug 2026; status: recruiting.
02
Drugs
ketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT07680140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07680140.